All In Biotech

Drug Trial Radar · NCT06690775

CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.

Catalina-2: A Phase 2 Study Evaluating the Efficacy and Safety of TORL-1-23 in Women With Advanced Platinum-Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal and Fallopian Tube Cancers) Expressing Claudin 6

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 230 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

230

Planned (sponsor's estimate)

Start

Nov 20, 2024

Primary completion

Oct 2027

Study completion Dec 2027

Sponsor

Lead sponsor
TORL Biotherapeutics, LLCIndustry
Sponsor type
Industry
Collaborators
European Network of Gynaecological Oncological Trial Groups (ENGOT)
First posted
Nov 15, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 2 study to evaluate the safety and efficacy of TORL-1-23 in patients with advanced ovarian cancer.

Conditions

  • Epithelial Ovarian Cancer
  • Primary Peritoneal
  • Fallopian Tube Cancer
  • Endometrioid Ovarian Cancer

Interventions

  • TORL-1-23Drug

    2.4mg/kg intravenous infusion on Day 1 of every 3-week cycle.

  • TORL-1-23Drug

    3.0 mg/kg intravenous infusion on Day 1 of every 3-week cycle.

  • TORL-1-23Drug

    3.4 mg/kg intravenous infusion on Day 1 of every 3-week cycle.

  • Pegfilgrastim (drug)Drug

    6.0 mg subcutaneous injection on Day 4 of each cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To assess the efficacy of TORL-1-23 as a monotherapy in women with advanced PROC expressing CLDN6Time frame: At predefined intervals from Dose 1 until documented disease progression, total overall study duration approximately 40 months

Locations

81 sites in 13 countries. Site status is shown where the registry gives one.

  • Mayo Clinic Hospital

    Phoenix, Arizona

  • TMC HealthCare

    Tucson, Arizona

  • City of Hope National Medical Center

    Duarte, California

  • Providence St. Jude Medical Center

    Fullerton, California

  • UCLA - JCCC Clinical Research Unit

    Los Angeles, California

  • Stanford Cancer Center

    Palo Alto, California

  • SCRI - Sansum Clinic

    Santa Barbara, California

  • University of Colorado Hospital - Anschutz Cancer Pavilion

    Aurora, Colorado

  • Smilow Cancer Hospital at Yale - New Haven

    New Haven, Connecticut

  • Mayo Clinic Florida

    Jacksonville, Florida

  • Winship Cancer Institute, Emory University

    Atlanta, Georgia

  • University of Chicago Medical Center

    Chicago, Illinois

  • SCRI - Maryland Oncology Hematology, P.A.

    Annapolis, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

  • SCRI - Minnesota Oncology Hematology, P.A.

    Minneapolis, Minnesota

  • University of Minnesota

    Minneapolis, Minnesota

  • Mayo Clinic

    Rochester, Minnesota

  • Washington University

    St Louis, Missouri

  • Rutgers Cancer Institute

    New Brunswick, New Jersey

  • Duke Cancer Center

    Durham, North Carolina

  • The James Cancer Hospital and Solove Research Institute - Ohio State University

    Columbus, Ohio

  • Stephenson Cancer Center at the University of Oklahoma

    Oklahoma City, Oklahoma

  • SCRI - Northwest Cancer Specialists, P.C.

    Portland, Oregon

  • SCRI - Alliance Cancer Specialists, PC

    Doylestown, Pennsylvania

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • The West Clinic, PLLC dba West Cancer Center

    Germantown, Tennessee

  • University of Texas Southwestern Medical Center

    Dallas, Texas

  • SCRI - Texas Oncology

    Fort Worth, Texas

  • SCRI - Virginia Oncology Associates

    Norfolk, Virginia

  • Providence Swedish Cancer Institute

    Seattle, Washington

  • Monash Medical Centre

    Clayton, Melbourne, Australia

  • Blacktown Hospital

    Blacktown, New South Wales, Australia

  • Icon Cancer Centre Chermside

    Chermside, Queensland, Australia

  • Flinders Medical Centre

    Bedford Park, South Australia, Australia

  • Linear Clinical Research

    Perth, Western Australia, Australia

  • Medizinische Universitat Landeskrankenhaus Graz

    Graz, Styria, Austria

  • Universitatsklinik Innsbruck

    Innsbruck, Tyrol, Austria

  • Ordensklinikum Linz

    Linz, Upper Austria, Austria

  • Antwerp University Hospital (UZA)

    Edegem, Antwerp, Belgium

  • Cliniques Universitaires Saint-Luc

    Woluwe-Saint-Lambert, Brussels Capital, Belgium

Showing 40 of 81 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.